AstraZeneca (STU:ZEGA) Moat Score: 7/10 (As of Jul. 09, 2026)


STU:ZEGA AstraZeneca PLC STU:ZEGA
87 GF Score
Price €78.00
GF Value €73.55
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Moat Score?

AstraZeneca STU:ZEGA +1.30% 87 Moat Score is 7 as of Jul. 09, 2026. GuruFocus rates STU:ZEGA with a GF Score™ of 87/100 and a GF Value™ of €73.55. The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, AstraZeneca ranks better than 98.64% on this metric.

AstraZeneca has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

AstraZeneca has Wide Moat: AstraZeneca benefits from strong intellectual property with a robust patent portfolio, significant R&D capabilities, and a strong brand in pharmaceuticals. These factors, combined with regulatory barriers and economies of scale, provide durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AstraZeneca might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

AstraZeneca  (STU:ZEGA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AstraZeneca Moat Score Related Terms

STU:ZEGA vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Moat Score distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Moat Score falls into.


STU:ZEGA
87GF Score
AstraZeneca PLC STU:ZEGA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
AstraZeneca (STU:ZEGA) has a Moat Score of 7 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AstraZeneca ranks #14 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is AstraZeneca's Moat Score too high?
AstraZeneca's current Moat Score is 7. Based on the distribution chart, AstraZeneca ranks #14 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #14 out of 1031 companies for Moat Score. This places AstraZeneca in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. AstraZeneca's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current Moat Score of 7. The stock's GF Value™ is €73.55, compared to a current price of €78.00 — trading 6.1% above its estimated fair value. The current Moat Score is 7. AstraZeneca's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current Moat Score is 7 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €78.00 is trading 6.1% above its estimated GF Value™ of €73.55.

Key valuation signals for STU:ZEGA:

  • Moat Score: 7
  • GF Value™: €73.55 vs. price of €78.00 (6.1% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for STU:ZEGA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€73.55
GF Value